Effect observation of bevacizumab combined with DDP chemotherapy in treatment of patients with non-small cell lung cancer

Objective To observe the effect of bevacizumab combined with DDP chemotherapy(cisplatin plus docetaxel)on the levels of serum vascular endothelial growth factor(VEGF), hypoxia-inducible factor-1α(HIF-1α)and stromal cell-derived factor-1α(SDF-1α)in patients with non-small cell lung cancer(NSCLC). Methods Totally 64 patients with NSCLC were randomly divided into two groups, with 32 cases in each group. Control group was treated with DDP chemotherapy, while observation group was treated with bevacizumab on the basis of the control group. Clinical efficacy, incidence of toxic and side effects, levels of serum VEGF-A, VEGF-B, VEGF-C, carbohydrate antigen 19-9(CA199), carcinoembryonic antigen(CEA), cytokeratin 19 fragment(CYFRA21-1)and expressions of mRNA of HIF-1α and SDF-1α before and after treatment were compared between two groups. The survival rates at 6, 12 and 24 months of follow-up were compared between the two groups. Results The objective response rate and disease control rate in the observation group were significantly higher than those in the control group(P<0.05). After treatment, the levels of serum VEGF-A, VEGF-B, VEGF-C, CA199, CEA, CYFRA21-1 and the expressions of mRNA of HIF-1α and SDF-1α in the observation group were significantly lower than those in the control group(P<0.05). There was no significant difference in incidence of toxic and side effects between two groups(P>0.05). At 24 months of follow-up, the survival rate of the observation group was significantly higher than that of the control group(P<0.05). Conclusion Bevacizumab combined with DDP chemotherapy can significantly reduce the serum levels of VEGF, CA199, CEA and CYFRA21-1, inhibit - the expressions of HIF-1α and SDF-1α, increase the therapeutic effect and survival rate, and has higher safety.